Response to comment on "Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer"

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5341-5342

  Yu, Jinpu ^a   Wang, Yue ^a   Yan, Fang ^b   Li, Hui ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; N METHYLTRYPTOPHAN; STAT3 PROTEIN;

BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPH NODE METASTASIS; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; UPREGULATION;

BREAST NEOPLASMS; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MYELOID CELLS;

EID: 84878030003     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1390024     Document Type: Letter

References (7)

1. Yue, W., B. H. Yang, H. Li, S. Cao, X. B. Ren, and J. P. Yu. 2013. IDO+ DCs and signalling pathways. Curr. Cancer Drug Targets. PMID 23369095.
2. Medzhitov, R., E. M. Shevach, G. Trinchieri, A. L. Mellor, D. H. Munn, S. Gordon, P. Libby, G. K. Hansson, K. Shortman, C. Dong, et al. 2011. Highlights of 10 years of immunology in Nature Reviews Immunology. Nat. Rev. Immunol. 11: 693-702.
3. Löb, S., A. Königsrainer, H. G. Rammensee, G. Opelz, and P. Terness. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9: 445-452.
4. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
5. Macchiarulo, A., E. Camaioni, R. Nuti, and R. Pellicciari. 2009. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 37: 219-229.
6. Opitz, C. A., U. M. Litzenburger, U. Opitz, F. Sahm, K. Ochs, C. Lutz, W. Wick, and M. Platten. 2011. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS ONE 6: e19823 10.1371/journal.pone.0019823.
7. Sørensen, R. B., S. R. Hadrup, I. M. Svane, M. C. Hjortsø, P. Thor Straten, and M. H. Andersen. 2011. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117: 2200-2210.